Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds–synthesis, biological activity, and structural evaluation

Abstract Schizophrenia is a chronic mental disorder that is not satisfactorily treated with available antipsychotics. The presented study focuses on the search for new antipsychotics by optimising the compound D2AAK3, a multi-target ligand of G-protein-coupled receptors (GPCRs), in particular D2, 5-HT1A, and 5-HT2A receptors. Such receptor profile may be beneficial for the treatment of schizophrenia. Compounds 1–16 were designed, synthesised, and subjected to further evaluation. Their affinities for the above-mentioned receptors were assessed in radioligand binding assays and efficacy towards them in functional assays. Compounds 1 and 10, selected based on their receptor profile, were subjected to in vivo tests to evaluate their antipsychotic activity, and effect on memory and anxiety processes. Molecular modelling was performed to investigate the interactions of the studied compounds with D2, 5-HT1A, and 5-HT2A receptors on the molecular level. Finally, X-ray study was conducted for compound 1, which revealed its stable conformation in the solid state.

[1]  E. Motomura,et al.  Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation , 2023, International journal of molecular sciences.

[2]  M. Loza,et al.  Multitarget Derivatives of D2AAK1 as Potential Antipsychotics: The Effect of Substitution in the Indole Moiety , 2022, ChemMedChem.

[3]  M. Tonelli.  One step away from the breakthrough of TAAR1 agonists for the treatment of neuropsychiatric disorders. , 2022, Current medicinal chemistry.

[4]  David E. Gloriam,et al.  Structural insights into the lipid and ligand regulation of serotonin receptors , 2021, Nature.

[5]  A. Kaczor,et al.  N-(3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propyl)-1H-indazole-3-carboxamide (D2AAK3) as a potential antipsychotic: In vitro, in silico and in vivo evaluation of a multi-target ligand , 2021, Neurochemistry International.

[6]  A. Kaczor,et al.  N-(2-Hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1H- benzimidazol-1-yl)propyl]piperidine-4-Carboxamide (D2AAK4), a Multi-Target Ligand of Aminergic GPCRs, as a Potential Antipsychotic , 2020, Biomolecules.

[7]  S. Iwata,et al.  Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine , 2019, Nature Structural & Molecular Biology.

[8]  A. Kaczor,et al.  Multi-Target Approach for Drug Discovery against Schizophrenia , 2018, International journal of molecular sciences.

[9]  A. Kaczor,et al.  Current Concepts and Treatments of Schizophrenia , 2018, Molecules.

[10]  Anat Levit,et al.  STRUCTURE OF THE D2 DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE , 2018, Nature.

[11]  M. Yarim,et al.  Density functional computational and X-ray studies on pharmaceutical compound 1-{3-[4-(4-fluorophenyl)piperazin-1-yl]propyl}-1H-indole , 2017 .

[12]  R. Jiang,et al.  Synthesis, crystal structure, biological evaluation, and molecular docking studies of quinoline-arylpiperazine derivative as potent α 1A -adrenoceptor antagonist , 2017 .

[13]  Shanming Kuang,et al.  Crystal form control and particle size control of RG3487, a nicotinic α7 receptor partial agonist. , 2016, International journal of pharmaceutics.

[14]  B. Budzyńska,et al.  In vitro, molecular modeling and behavioral studies of 3-{[4-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl}-1,2-dihydroquinolin-2-one (D2AAK1) as a potential antipsychotic , 2016, Neurochemistry International.

[15]  Peter Kolb,et al.  Structure‐Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics , 2016, ChemMedChem.

[16]  R. Stackman,et al.  The role of serotonin 5-HT2A receptors in memory and cognition , 2015, Front. Pharmacol..

[17]  S. Chance,et al.  The neuropathology of schizophrenia: A selective review of past studies and emerging themes in brain structure and cytoarchitecture , 2015, Neuroscience.

[18]  A. Oliver,et al.  Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates. , 2014, Bioorganic & medicinal chemistry letters.

[19]  F. Sanz,et al.  Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles. , 2014, European journal of medicinal chemistry.

[20]  M. Kołaczkowski,et al.  Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia , 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  J. Leppänen,et al.  Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. , 2013, Journal of medicinal chemistry.

[22]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[23]  Gregory M. Miller,et al.  The emerging role of trace amine‐associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity , 2011, Journal of neurochemistry.

[24]  Woody Sherman,et al.  Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods , 2010, J. Cheminformatics.

[25]  Woody Sherman,et al.  Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..

[26]  David Calkins,et al.  Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..

[27]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.

[28]  D. Weiner,et al.  Pharmacology of N-desmethylclozapine. , 2007, Pharmacology & therapeutics.

[29]  A. Argiolas,et al.  2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. , 2006, Journal of medicinal chemistry.

[30]  Richard De La Garza,et al.  Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models. , 2003, Stress.

[31]  J. Kossakowski,et al.  Synthesis and Structural Characterization of Aminoalkanol Derivatives of 2,3-Dihydro-2,2-dimethyl-7-benzofuranol with an Expected β-Adrenolytic and / or Anxiolytic Activity , 2002 .

[32]  L H Parsons,et al.  Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.

[34]  Raymond E. Davis,et al.  Patterns in Hydrogen Bonding: Functionality and Graph Set Analysis in Crystals , 1995 .

[35]  S. File,et al.  5-HT1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively. , 1994, European journal of pharmacology.

[36]  P. Leff,et al.  Further concerns over Cheng-Prusoff analysis. , 1993, Trends in pharmacological sciences.

[37]  C. Haasnoot,et al.  The Conformation of Six-Membered Rings Described by Puckering Coordinates Derived from Endocyclic Torsion Angles , 1992 .

[38]  D. Cremer,et al.  General definition of ring puckering coordinates , 1975 .

[39]  R. Bradshaw,et al.  The Gabriel Synthesis of Primary Amines , 1968 .

[40]  J. Crippa,et al.  Animal models for predicting the efficacy and side effects of antipsychotic drugs. , 2013, Revista brasileira de psiquiatria.